Weng Kee Wong

List of Publications by Year
in descending order

124	2,670	257450 24	243625 44
papers	citations	h-index	g-index

144	144	144	1788
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial. Arthritis and Rheumatism, 2000, 43, 2445-2454.	6.7	252
2	Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis and Rheumatism, 2002, 46, 2983-2989.	6.7	194
3	On the Equivalence of Constrained and Compound Optimal Designs. Journal of the American Statistical Association, 1994, 89, 687-692.	3.1	136
4	A multicenter, randomized, doubleâ€blind, placeboâ€controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in lateâ€phase disease. Arthritis and Rheumatism, 2008, 58, 1810-1822.	6.7	99
5	Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 2372-2380.	6.7	96
6	The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial. Arthritis and Rheumatism, 2001, 44, 653-661.	6.7	96
7	Design Issues for the Michaelisâ€“Menten Model. Journal of Theoretical Biology, 2002, 215, 1-11.	1.7	63
8	Recent developments in nonregular fractional factorial designs. Statistics Surveys, 2009, 3, .	11.3	63
9	Minimax optimal designs via particle swarm optimization methods. Statistics and Computing, 2015, 25, 975-988.	1.5	53
10	Application of fractional factorial designs to study drug combinations. Statistics in Medicine, 2013, 32, 307-318.	1.6	50
11	Association of tumor necrosis factor Î± polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis and Rheumatism, 2006, 54, 1105-1116.	6.7	49
12	Optimal Design for Goodness-of-Fit of the Michaelisâ€“Menten Enzyme Kinetic Function. Journal of the American Statistical Association, 2005, 100, 1370-1381.	3.1	40
13	A Modified Particle Swarm Optimization Technique for Finding Optimal Designs for Mixture Models. PLoS ONE, 2015, 10, e0124720.	2.5	36
14	Minimax d-optimal designs for item response theory models. Psychometrika, 2000, 65, 377-390.	2.1	35
15	Optimal responseâ€adaptive randomized designs for multiâ€armed survival trials. Statistics in Medicine, 2011, 30, 2890-2910.	1.6	35
16	DESIGNING STUDIES FOR DOSE RESPONSE. , 1996, 15, 343-359.		33
17	Optimizing Two-Level Supersaturated Designs Using Swarm Intelligence Techniques. Technometrics, 2016, 58, 43-49.	1.9	31
18	Optimum treatment allocation rules under a variance heterogeneity model. Statistics in Medicine, 2008, 27, 4581-4595.	1.6	30

#	Article	IF	Citations
19	Using animal instincts to design efficient biomedical studies via particle swarm optimization. Swarm and Evolutionary Computation, 2014, 18, 1-10.	8.1	30
20	Comparing robust properties of A, D, E and G-optimal designs. Computational Statistics and Data Analysis, 1994, 18, 441-448.	1.2	28
21	The need of considering the interactions in the analysis of screening designs. Journal of Chemometrics, 2009, 23, 545-553.	1.3	28
22	The relationship between socioeconomic status and recently diagnosed rheumatoid arthritis. Arthritis and Rheumatism, 1996, 9, 457-462.	6.7	27
23	Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. Journal of Rheumatology, 2004, 31, 1686-92.	2.0	26
24	E-optimal designs for the Michaelisâ€“Menten model. Statistics and Probability Letters, 1999, 44, 405-408.	0.7	25
25	Varying-Coefficient Semiparametric Model Averaging Prediction. Biometrics, 2018, 74, 1417-1426.	1.4	25
26	A Graphical Method for Finding Maximin Efficiency Designs. Biometrics, 2000, 56, 113-117.	1.4	24
27	Adaptive clinical trial designs for phase I cancer studies. Statistics Surveys, 2014, 8, .	11.3	24
28	Correlation of single time-point damage scores with observed progression of radiographic damage during the first 6 years of rheumatoid arthritis. Journal of Rheumatology, 2003, 30, 705-13.	2.0	24
29	Finding Bayesian Optimal Designs for Nonlinear Models: A Semidefinite Programmingâ€Based Approach. International Statistical Review, 2015, 83, 239-262.	1.9	23
30	Standardized maximim D -optimal designs for enzyme kinetic inhibition models. Chemometrics and Intelligent Laboratory Systems, 2017, 169, 79-86.	3.5	23
31	d-QPSO: A Quantum-Behaved Particle Swarm Technique for Finding D-Optimal Designs With Discrete and Continuous Factors and a Binary Response. Technometrics, 2019, 61, 77-87.	1.9	23
32	Prediction of progression in idiopathic pulmonary fibrosis using CT scans at baseline: A quantum particle swarm optimization - Random forest approach. Artificial Intelligence in Medicine, 2019, 100, 101709.	6.5	22
33	Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 2743-2750.	6.7	21
34	MULTIPLE-OBJECTIVE DESIGNS IN A DOSE-RESPONSE EXPERIMENT. Journal of Biopharmaceutical Statistics, 2000, 10, 1-14.	0.8	21
35	Bayesian D-optimal designs on a fixed number of design points for heteroscedastic polynomial models. Biometrika, 1998, 85, 869-882.	2.4	20
36	Recent advances in multipleâ€objective design strategies. Statistica Neerlandica, 1999, 53, 257-276.	1.6	20

#	Article	IF	Citations
37	Optimal treatment allocation in comparative biomedical studies. , 2000, 19, 639-648.		20
38	Bayesian optimal designs for estimating a set of symmetrical quantiles. Statistics in Medicine, 2001, 20, 123-137.	1.6	20
39	Handling missing data issues in clinical trials for rheumatic diseases. Contemporary Clinical Trials, 2011, 32, 1-9.	1.8	20
40	Optimal Treatment Allocations in Space and Time for On-Line Control of an Emerging Infectious Disease. Journal of the Royal Statistical Society Series C: Applied Statistics, 2018, 67, 743-789.	1.0	20
41	Finding High-Dimensional D-Optimal Designs for Logistic Models via Differential Evolution. IEEE Access, 2019, 7, 7133-7146.	4.2	20
42	Optimal Designs When the Variance Is A Function of the Mean. Biometrics, 1999, 55, 925-929.	1.4	19
43	Classifying structural joint damage in rheumatoid arthritis as progressive or nonprogressive using a composite definition of joint radiographic change: A preliminary proposal. Arthritis and Rheumatism, 2004, 50, 1083-1096.	6.7	19
44	A semi-infinite programming based algorithm for finding minimax optimal designs for nonlinear models. Statistics and Computing, 2014, 24, 1063-1080.	1.5	19
45	A Semi-Infinite Programming based algorithm for determining T-optimum designs for model discrimination. Journal of Multivariate Analysis, 2015, 135, 11-24.	1.0	19
46	A modelâ€based multithreshold method for subgroup identification. Statistics in Medicine, 2019, 38, 2605-2631.	1.6	19
47	Multiple-objective optimal designs for the logit model. Communications in Statistics - Theory and Methods, 1998, 27, 1581-1592.	1.0	17
48	Application of imperialist competitive algorithm to find minimax and standardized maximin optimal designs. Computational Statistics and Data Analysis, 2017, 113, 330-345.	1.2	16
49	Early palliative care: the surprise question and the palliative care screening toolâ€”better together. BMJ Supportive and Palliative Care, 2022, 12, 211-217.	1.6	16
50	Particle swarm optimization for searching efficient experimental designs: A review. Wiley Interdisciplinary Reviews: Computational Statistics, 2022, 14, .	3.9	16
51	Optimal Bayesian designs for models with partially specified heteroscedastic structure. Annals of Statistics, 1996, 24, 2108.	2.6	15
52	Optimal two-point designs for the michaelis-menten model with heteroscedastic errors. Communications in Statistics - Theory and Methods, 1998, 27, 1503-1516.	1.0	15
53	Maximin Optimal Designs for Cluster Randomized Trials. Biometrics, 2017, 73, 916-926.	1.4	14
54	Extended two-stage adaptive designs with three target responses for phase II clinical trials. Statistical Methods in Medical Research, 2018, 27, 3628-3642.	1.5	14

#	Article	IF	Citations
55	Optimal design of experiments with anticipated pattern of missing observations. Journal of Theoretical Biology, 2004, 228, 251-260.	1.7	13
56	An augmented approach to the desirability function. Journal of Applied Statistics, 2012, 39, 599-613.	1.3	13
57	Using Differential Evolution to design optimal experiments. Chemometrics and Intelligent Laboratory Systems, 2020, 199, 103955.	3.5	13
58	Particle swarm based algorithms for finding locally and Bayesian D-optimal designs. Journal of Statistical Distributions and Applications, 2019, 6, .	1.2	12
59	A Metaheuristic Adaptive Cubature Based Algorithm to Find Bayesian Optimal Designs for Nonlinear Models. Journal of Computational and Graphical Statistics, 2019, 28, 861-876.	1.7	12
60	Optimal minimax designs for prediction in heteroscedastic models. Journal of Statistical Planning and Inference, 1998, 69, 371-383.	0.6	11
61	Assessing disease progression using a composite endpoint. Statistical Methods in Medical Research, 2007, 16, 31-49.	1.5	11
62	Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. Statistical Methods in Medical Research, 2007, 16, 13-29.	1.5	11
63	Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. Lupus Science and Medicine, 2019, 6, e000321.	2.7	11
64	CVXâ€based algorithms for constructing various optimal regression designs. Canadian Journal of Statistics, 2019, 47, 374-391.	0.9	11
65	Optimal exact designs of experiments via Mixed Integer Nonlinear Programming. Statistics and Computing, 2020, 30, 93-112.	1.5	11
66	Competitive swarm optimizer with mutated agents for finding optimal designs for nonlinear regression models with multiple interacting factors. Memetic Computing, 2020, 12, 219-233.	4.0	11
67	Optimal minimax designs over a prespecified interval in a heteroscedastic polynomial model. Statistics and Probability Letters, 2008, 78, 1914-1921.	0.7	10
68	Polymer properties associated with chemical permeation performance of disposable nitrile rubber gloves. Journal of Applied Polymer Science, 2015, 132, .	2.6	10
69	On Optimal Designs for Clinical Trials: An Updated Review. Journal of Statistical Theory and Practice, 2020, 14, 1.	0.5	10
70	An overview of healthcare data analytics with applications to the COVID-19 pandemic. IEEE Transactions on Big Data, 2021, , 1-1.	6.1	10
71	On the equivalence of D and G-optimal designs in heteroscedastic models. Statistics and Probability Letters, 1995, 25, 317-321.	0.7	9
72	Optimum treatment allocation for dual-objective clinical trials with binary outcomes. Communications in Statistics - Theory and Methods, 2000, 29, 957-974.	1.0	9

#	Article	IF	Citations
73	Dual-Objective Bayesian Optimal Designs for a Dose-Ranging Study. Drug Information Journal, 2000, 34, 421-428.	0.5	9
74	A semi-parametric analysis for identifying Scleroderma patients responsive to an anti-fibrotic agent. Contemporary Clinical Trials, 2009, 30, 105-113.	1.8	9
75	Adaptive grid semidefinite programming for finding optimal designs. Statistics and Computing, 2018, 28, 441-460.	1.5	9
76	Pharmacometrics meets statisticsâ€"A synergy for modern drug development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1134-1149.	2.5	9
77	Optimal designs for dose-finding experiments in toxicity studies. Bernoulli, 2009, 15, .	1.3	8
78	Optimal Experimental Design Strategies for Detecting Hormesis. Risk Analysis, 2011, 31, 1949-1960.	2.7	8
79	Analysis of a composite endpoint with longitudinal and timeâ€toâ€event data. Statistics in Medicine, 2011, 30, 1018-1027.	1.6	8
80	Model-based optimal design of experiments â€"Semidefinite and nonlinear programming formulations. Chemometrics and Intelligent Laboratory Systems, 2016, 151, 153-163.	3.5	8
81	G-optimal designs for hierarchical linear models: an equivalence theorem and a nature-inspired meta-heuristic algorithm. Soft Computing, 2021, 25, 13549-13565.	3.6	8
82	RARtool: AMATLABSoftware Package for Designing Response-Adaptive Randomized Clinical Trials with Time-to-Event Outcomes. Journal of Statistical Software, 2015, 66, .	3.7	8
83	Optimal designs for the power logistic model. Journal of Statistical Computation and Simulation, 2004, 74, 779-791.	1.2	7
84	Multiple-Objective Optimal Designs for Studying the Dose Response Function and Interesting Dose Levels. International Journal of Biostatistics, 2015, 11, 253-71.	0.7	7
85	Detecting the violation of variance homogeneity in mixed models. Statistical Methods in Medical Research, 2016, 25, 2506-2520.	1.5	7
86	Optimal Designs for Multi-Response Nonlinear Regression Models With Several Factors via Semidefinite Programming. Journal of Computational and Graphical Statistics, 2019, 28, 61-73.	1.7	7
87	Hybrid algorithms for generating optimal designs for discriminating multiple nonlinear models under various error distributional assumptions. PLoS ONE, 2020, 15, e0239864.	2.5	7
88	On the equivalence of optimality design criteria for the placeboâ€"treatment problem. Statistics and Probability Letters, 2005, 74, 337-346.	0.7	6
89	Selection of covariance patterns for longitudinal data in semi-parametric models. Statistical Methods in Medical Research, 2010, 19, 183-196.	1.5	6
90	Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives. Therapeutic Innovation and Regulatory Science, 2014, 48, 601-612.	1.6	6

#	Article	IF	Citations
91	Constructing robust and efficient experimental designs in groundwater modeling using a Galerkin method, proper orthogonal decomposition, and metaheuristic algorithms. PLoS ONE, 2021, 16, e0254620.	2.5	6
92	Doubly adaptive biased coin designs for balancing competing objectives in time-to-event trials. Statistics and Its Interface, 2012, 5, 401-413.	0.3	6
93	Optimal designs for composed models in pharmacokineticâ€“pharmacodynamic experiments. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 295-311.	1.8	5
94	Optimal experimental designs for ordinal models with mixed factors for industrial and healthcare applications. Journal of Quality Technology, 2022, 54, 184-196.	2.5	5
95	VNM: An R Package for Finding Multiple-Objective Optimal Designs for the 4-Parameter Logistic Model. Journal of Statistical Software, 2018, 83, .	3.7	5
96	Bayesian Optimal Designs for a Quantal Dose-Response Study with Potentially Missing Observations. Journal of Biopharmaceutical Statistics, 2006, 16, 679-693.	0.8	4
97	A reanalysis of a longitudinal scleroderma clinical trial using non-ignorable missingness models. Journal of Statistical Planning and Inference, 2007, 137, 3848-3858.	0.6	4
98	Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: A baseline analysis. Contemporary Clinical Trials, 2011, 32, 160-168.	1.8	4
99	Web-based tools for finding optimal designs in biomedical studies. Computer Methods and Programs in Biomedicine, 2013, 111, 701-710.	4.7	4
100	Examining radiographic outcomes over time. Rheumatology International, 2014, 34, 271-279.	3.0	4
101	An algorithm based on semidefinite programming for finding minimax optimal designs. Computational Statistics and Data Analysis, 2018, 119, 99-117.	1.2	4
102	T-optimal designs for multi-factor polynomial regression models via a semidefinite relaxation method. Statistics and Computing, 2019, 29, 725-738.	1.5	4
103	Metaheuristics for pharmacometrics. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1297-1309.	2.5	4
104	Phase II two-stage single-arm clinical trials for testing toxicity levels. Communications for Statistical Applications and Methods, 2019, 26, 163-173.	0.3	4
105	A model-based approach to designing developmental toxicology experiments using sea urchin embryos. Archives of Toxicology, 2022, 96, 919-932.	4.2	4
106	Design issues for population growth models. Journal of Applied Statistics, 2011, 38, 501-512.	1.3	3
107	Optimal Design of Multiple-Objective Lot Quality Assurance Sampling (LQAS) Plans. Biometrics, 2019, 75, 572-581.	1.4	3
108	Using SeDuMi to find various optimal designs for regression models. Statistical Papers, 2019, 60, 1583-1603.	1.2	3

#	Article	IF	Citations
109	A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images. Contemporary Clinical Trials, 2021, 104, 106333.	1.8	3
110	Discussion on From Start to Finish: a Framework for the Production of Small Area Official Statistics. Journal of the Royal Statistical Society Series A: Statistics in Society, 2018, 181, 969-970.	1.1	3
111	Robustness properties of minimally-supported Bayesian D-optimal designs for heteroscedastic models. Canadian Journal of Statistics, 2001, 29, 633-647.	0.9	2
112	Data-driven desirability function to measure patientsâ€™ disease progression in a longitudinal study. Journal of Applied Statistics, 2016, 43, 783-795.	1.3	2
113	Design: Designing Studies for Dose Response. , 2005, , 315-333.		1
114	Discussion: A general approach to -optimal designs for weighted univariate polynomial regression models. Journal of the Korean Statistical Society, 2010, 39, 27-30.	0.4	1
115	Optimal designs for asymmetric sigmoidal response curves in bioassays and immunoassays. Statistical Methods in Medical Research, 2020, 29, 421-436.	1.5	1
116	Spatial two-stage designs for phase II clinical trials. Computational Statistics and Data Analysis, 2022, 169, 107420.	1.2	1
117	Optimal designs for health risk assessments using fractional polynomial models. Stochastic Environmental Research and Risk Assessment, 2022, 36, 2695-2710.	4.0	1
118	Equivalence theorems for c and DAâ€optimality for linear mixed effects models with applications to multitreatment group assignments in health care. Scandinavian Journal of Statistics, 0, , .	1.4	1
119	Orthogonal array composite designs for drug combination experiments with applications for tuberculosis. Statistics in Medicine, 2022, , .	1.6	1
120	Robustness Properties of Multiple-Objective Optimal Designs for a Bi-Exponential Model. Drug Information Journal, 2005, 39, 223-232.	0.5	0
121	Title is missing!. , 2020, 15, e0239864.		0
122	Title is missing!. , 2020, 15, e0239864.		0
123	Title is missing!. , 2020, 15, e0239864.		0
124	Title is missing!. , 2020, 15, e0239864.		0